
Starting Therapy for Intermediate-Risk Myelofibrosis Based on Hemoglobin
Mark J. Fesler, MD Hematologic Malignancy Specialist Director of Bispecific Immunotherapy St. Luke’s Center for Cancer Care Chesterfield, MO CASE SUMMARY A 68-year-old woman presented to her physician with symptoms of mild fatigue. Spleen was palpable 6 to …